Steady Expansion Forecast for Cancer Immunotherapy Market, Projected to Reach $189.5 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cancer Immunotherapy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the market size for cancer immunotherapy has seen a significant increase. Its expansion is projected to continue from $110.91 billion in 2024 to $124.09 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. The historical period's growth is largely due to the surge in cancer cases, the preference for immunotherapy over traditional treatments, the expansion of research and development activities to tackle specific diseases, the improved effectiveness and precision of recent therapies, and the growing acknowledgment of the shortcomings of conventional cancer treatments.

Cancer Immunotherapy Market Size Forecast: What's the Projected Valuation by 2029?
The market size for cancer immunotherapy is anticipated to experience a significant expansion in the coming years. The market is forecasted to reach around "$189.5 billion in 2029", growing at a compound annual growth rate (CAGR) of 11.2%. The projected elevation over the forecast period is due to factors such as the approval of new cancer immunotherapies, the increasing demand for tailored medical treatments, the upsurge in cancer detection rates, augmented funding for clinical trials to pioneer breakthrough treatments, and an increasing consciousness about cancer immunotherapy. Noteworthy trends for the forecast timeframe consist of the emergence of adaptive cell therapies such as car-t cells, the investigation of oncolytic viruses in cancer immunotherapy, the production of individualized cancer vaccines, the application of artificial intelligence in immunotherapy studies, and a raised focus on real-world evidence and patient outcomes in treatment decisions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

What Are the Drivers Transforming the Cancer Immunotherapy Market?
The increase in the number of cancer cases is anticipated to stimulate the cancer immunotherapy market. Factors leading to a worldwide rise in cancer incidence involve tobacco and alcohol consumption, obesity, inactive lifestyles, and environmental influences. This surge in cancer instances is expected to augment the need for cancer immunotherapies as patients are more often resorting to medical treatments that proffer higher recuperation rates with less discomfort. For example, as per the European Union Science Hub, a Belgium-based establishment of the European Commission's Joint Research Centre, new cancer instances escalated by 2.3% over the last two years, touching 2.74 million in 2022, as reported in October 2023. Similarly, cancer deaths rose by 2.4% over the last two years. Hence, the increasing incidences of cancer are anticipated to fuel the demand for cancer immunotherapy in the forecasted period.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Long-Term Trends Will Define the Future of the Cancer Immunotherapy Market?
A prevalent trend in the cancer immunotherapy market is the utilization of advanced technologies. The sector has witnessed a major upswing in innovative technologies and a plethora of therapies aimed at enabling the immune system to detect and combat tumors. The methods of immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy are all common. These state-of-the-art technologies promise to impact cancer treatment significantly. In October 2022, AstraZeneca plc, a pharmaceutical and biotech firm based in the UK, said it had earned approval for a new drug, Capivasertib, to be used in partnership with Faslodex. This cancer immunotherapeutic is a breakthrough for breast cancer treatment, as it works effectively in managing recurrence or progression following endocrine therapy in locally advanced or metastatic breast cancer with low or no human epidermal growth factor receptor 2 (HER2).

Which Segments in the Cancer Immunotherapy Market Offer the Most Profit Potential?
The cancer immunotherapy market covered in this report is segmented -

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Which Firms Dominate the Cancer Immunotherapy Market by Market Share and Revenue in 2025?
Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

Which Regions Offer the Highest Growth Potential in the Cancer Immunotherapy Market?
North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6768

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Reach Out to Us
Speak With Our Expert:Saumya Sahay,
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267,
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.